Alexei V. Veselov

Alexei V. Veselov

Auto-generated profile, based on publicly available information

Alexei V. Veselov

National Medical Research Centre for Coloproctology named after A.N. Ryzhikh

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2019 in Koloproktologia
Verified
Journal Article
Open access
PDF file
YSYu. A. Shelygin
Yu. A. Shelygin
SFS. A. Frolov
S. A. Frolov
ATA. Yu. Titov
A. Yu. Titov
ЛБЛ. А. Благодарный
Л. А. Благодарный
SVS. V. Vasilyev
S. V. Vasilyev
VYV. V. Yanovoy
V. V. Yanovoy
КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ АССОЦИАЦИИ КОЛОПРОКТОЛОГОВ РОССИИ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ГЕМОРРОЯ

30 March 2017 in Koloproktologia
Verified
Journal Article
Open access
PDF file
YSYu. A. Shelygin
Yu. A. Shelygin
AVA. V. Veselov
A. V. Veselov
ASA. A. Serbina
A. A. Serbina
ОСНОВНЫЕ НАПРАВЛЕНИЯ ОРГАНИЗАЦИИ СПЕЦИАЛИЗИРОВАННОЙ КОЛОПРОКТОЛОГИЧЕСКОЙ ПОМОЩИ

5 December 2019 in Koloproktologia
Verified
Journal Article
Open access
PDF file
EBE. A. Belousova
E. A. Belousova
ВAВю I. Abdulganieva
Вю I. Abdulganieva
OAO. P. Alekseeva
O. P. Alekseeva
IBI. G. Bakulin
I. G. Bakulin
OVO. V. Vasilyeva
O. V. Vasilyeva
ЕЧЕ. Ю. Чашкова
Е. Ю. Чашкова
AIM: to demonstrate the first Russian experience with the use of tofaciminib (TOFA) for the treatment of moderate and severe UC in real clinical practice.PATIENTS AND METHODS: eighty-five patients with UC (aged 41.38±14.69 years, average disease duration 9.55±5.27 years, mild UC – 3.5%, moderate UC – 41.2%, severe – 52.9%, acute severe UC – 2.6%), resistant to corticosteroid therapy (36.5%) and biological agents (61.2%), were prescribed with TOFA at an induction dose of 10 mg 2 times a day, followed by a decrease in the dose to a maintenance dose (5 mg 2 times a day). Early clinical response, clinical and endoscopic remission, prevalence and dynamic of extraintestinal manifestations were assessed at 8 and 12 weeks of treatment, as well as safety and tolerability.RESULTS: Sixty-eight (80.0%) patients completed induction treatment with TOFA for 8 weeks, other patients continue to receive TOFA. A quick response within one week was detected in 41 (50.6%) patients, on average, on the 5th day of therapy. At the end of induction, 52 (76.5%) patients achieved clinical remission, 3 (4.4%) achieved a clinical response, 13 (19.1%) patients showed no positive changes. Of the 53 patients observed over 12 weeks, 41 (77.4%) had clinical remission, 6 (11.3%) had clinical improvement, and 6 (11.3%) patients had no response to the treatment. The changes of extraintestinal manifestations were positive: 55.2% of patients at week 8 and 77.8% of patients at week 12 showed clinical improvement, mainly in relation to the joint syndrome. One episode of herpes zoster infection, one case of anemia, were identified dur-ing 12 weeks of follow-up.CONCLUSION: TOFA in UC is effective in achieving a rapid clinical response, clinical remission and mucosal healing in patients who do not adequately respond to therapy with basic as well as biological drugs. Tofacitinib is an effective and safe therapeutic option for this challenging patient population.

29 December 2020 in Almanac of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DAD. I. Abdulganieva
D. I. Abdulganieva
ABA. L. Bakulev
A. L. Bakulev
EBE. A. Belousova
E. A. Belousova
AVA. V. Veselov
A. V. Veselov
TKT. V. Korotaeva
T. V. Korotaeva
OSO. B. Shchukina
O. B. Shchukina
Psoriasis (Ps), psoriatic arthritis (PsA), and inflammatory bowel diseases (IBDs) are characterized by a progressive course and commonly result in disability. Therefore, their early diagnosis with the assessment of a clinical phenotype and unfavorable prognostic factors and the timely initiation of therapy are important. The paper provides the expert consensus on the definition of the early stage of Ps, PsA, and IBDs, their treatment goals and main unfavorable prognostic factors. It also gives the rationale for the early use of biological agents in patients with immune-mediated inflammatory diseases.

1 October 2020 in Problems of Social Hygiene, Public Health and History of Medicine
Verified
Journal Article
Closed access
AVA V Veselov
A V Veselov
EBE A Belousova
E A Belousova
IBI G Bakulin
I G Bakulin
YUY P Uspenskiy
Y P Uspenskiy
RDR O Dreval
R O Dreval
VSV V Shipitsyn
V V Shipitsyn
To estimate the quality and availability of medical care for patients with ulcerative colitis (UC) and Crohn's disease (CD), to assess the impact of the economic burden of these diseases on the healthcare budget of Russia and to systematize the main problems in the organization of medical care and d …

16 May 2019 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
EFE. D. Fedorov
E. D. Fedorov
VVV. V. Veselov
V. V. Veselov
SKS. V. Kashin
S. V. Kashin
ETE. V. Tikhomirova
E. V. Tikhomirova
AVA. V. Veselov
A. V. Veselov
МВМ. Вольто
М. Вольто
Oral sulphate solution(OSS: sodium sulphate, potassium sulphate and magnesium sulphate) is a low-volume osmotic agent for cleansing the intestines.Aim: in a multicentre, prospective, randomized, 3rd phase study with two parallel groups, the effectiveness, safety and tolerability of OSS was evaluated in comparison with Macrogol 4000 with electrolytes (a reference preparation for bowel cleansing in Russia) in adult patients who were scheduled for routine diagnostic colonoscopy.Methods. This study was conducted in three Russian research centres during the March–December, 2015 period. Men and women over the age of 18 scheduled to undergo routine diagnostic colonoscopy were randomly assigned either to the OSS group or to the Macrogol group with a fractional use mode before the colonoscopy. The colonoscopy researchers were not aware of which preparation had been taken by the patients. Anonymized video records were centrally analysed by three experts. The primary end point was the proportion of patients with a successful bowel preparation for colonoscopy ≥ 6 points, as determined by the Boston Bowel Preparation Scale of quality assessment (BBPS scale).Results. 296 patients were randomized in the study (147 patients were treated with OSS, 149 patients received Macrogol); 294 participants were included in the Intention to Treat population (ITT-population), and 274 participants were included in the population of patients who completed the study according to the protocol (Per-Protocol; PP-population) (139 patients received OSS, 135 patients received Macrogol). The proportion of patients with a successful bowel preparation (BBPS ≥6 scores) was high in both groups (OSS [PP-population]: 97.2 % (95 % confidence interval [CI] 89.5–99.3), Macrogol [PP-population]: 97.7 % (95 % CI: 90.7–99.4)). The corrected difference between the groups was -0.5 % (95 % CI: -4.2–3.3), thereby demonstrating “no less effective” of OSS as compared to Macrogol. Compliance with the drug use regime was higher in the OSS group than in the Macrogol group (95.7 % versus 82.3 %, respectively, p-value = 0.0011, ITT-population).The most common symptom reported in patients was nausea (27.9 % in the OSS group and 12.9 % in the Macrogol group). The proportion of patients who developed nausea was significantly higher in the OSS group than in the Macrogol group (25.2 % compared with 10.2 % when taking the first dose of the preparation (p = 0.0008) and 19.7 % compared with 6.8 % when taking the second dose of the preparation (p = 0.0016)). Differences in other symptoms (bloating, abdominal pain or abdominal discomfort) between the groups were not significant, with the severity of symptoms being generally mild. The safety profile of the investigated preparations in patients withinflammatory bowel disease (IBD) in remission did not differ from that in the general patient population. The differences in terms of secondary endpoints were not identified, including BBPS assessment for different sections of the colon, the level of polyp detection, the duration and completeness of colonoscopy, and the investigator’s satisfaction with the procedure. The analysis by subgroups also did not reveal any significant differences.Conclusion. In this study, the “not less effectiveness” of the sulphate solution was demonstrated as compared to Macrogol in a fractional use mode. Both preparations were well tolerated. Despite the higher incidence of nausea in the OSS group, the patients showed significantly higher compliance with the OSS mode as compared to that of Macrogol. This study is registered with the ClinicalTrials.gov Registry of Clinical Trials, No. NCT02321462.Conflict of interest: this study was sponsored by Ipsen Pharma.Acknowledgements: the authors express their sincere gratitude to all the patients who participated in the study, as well as to specialists having provided medical care for the patients, researchers and employees of the participant research centres. The authors also express their appreciation to Olga Kapitonova, an employee of the Almedis company (Moscow, Russia) for her assistance in compiling medical texts, which activity was carried out under the financial support of the Ipsen company (Moscow, Russia) in accordance with the Good Publication Practice (GPP).